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Abstract
Vascular ageing in conditions such as atherosclerosis, diabetes and chronic kidney disease, is associated with the activation of the renin angio-
tensin system (RAS) and diminished expression of antioxidant defences mediated by the transcription factor nuclear factor erythroid 2-related
factor 2 (Nrf2). The anti-ageing hormone klotho promotes longevity and protects against cardiovascular and renal diseases. Klotho has been
shown to activate Nrf2 and attenuate oxidative damage in neuronal cells, however, the mechanisms by which it protects against vascular
smooth muscle cell VSMC dysfunction elicited by Angiotensin II (AngII) remain to be elucidated. AngII contributes to vascular ageing and
atherogenesis by enhancing VSMC oxidative stress, senescence and apoptosis. This study demonstrates that soluble klotho (1 nM, 24 hrs) sig-
nificantly induces expression of Nrf2 and the antioxidant enzymes haeme oxygenase (HO-1) and peroxiredoxin-1 (Prx-1) and enhances glu-
tathione levels in human aortic smooth muscle cells (HASMC). Silencing of Nrf2 attenuated the induction of HO-1 and Prx-1 expression by
soluble klotho. Furthermore, soluble klotho protected against AngII-mediated HASMC apoptosis and senescence via activation of Nrf2. Thus,
our findings highlight a novel Nrf2-mediated mechanism underlying the protective actions of soluble klotho in HAMSC. Targeting klotho may
thus represent a therapeutic strategy against VSMC dysfunction and cardiovascular ageing.
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Introduction
Age-related disorders including diabetes, hypertension and chronic
kidney disease are associated with activation of renin angiotensin sys-
tem (RAS) and increased risk of vascular disease [1–3]. AngII plays a
central role in the development of hypertension and atherosclerosis
through an increase in reactive oxygen species (ROS) generation and
down-regulation of endogenous antioxidant defence systems such as
Nrf2 [4–6]. AngII has been also shown to induce senescence and
apoptosis in vascular smooth muscle cells (VSMC) via activation of
the cell cycle regulation proteins p53 and p21 [7]. The redox-sensitive
transcription factor Nrf2 mediates endogenous antioxidant protection
against oxidative stress associated with cardiovascular pathologies
[8]. In response to a range of inducers, Nrf2 translocates into the
nucleus binding to the antioxidant response elements (ARE) in the
promoter region of target antioxidant defence genes such as haeme
oxygenase-1 (HO-1), peroxiredoxin-1 (Prx-1) and enzymes involved
in reduced glutathione (GSH) synthesis [9].
Klotho is a renal protein originally reported as a regulator of the
ageing process in mice [10–12]. Klotho deficiency is associated with
decreased lifespan and accelerated vascular ageing, whereas its over-
expression has been shown to confer vascular protection through
reduction in oxidative stress and arterial calcification [10]. Klotho is
not only predominantly expressed in the kidney as a membrane -pro-
tein but also exists as a circulating soluble form resulting from a pro-
teolytic cleavage [13].
Soluble klotho acts as a hormone that confers antioxidant, anti-
senescence and anti-apoptotic effects in endothelial and renal cells
[14, 15]. Nrf2 activation has been identified as a mechanism by which
klotho enhances antioxidant defences in neuronal and epithelial cells
[16, 17], however, to date the involvement of Nrf2 in klotho-mediated
vascular cell protection has not been investigated.
This study has examined the role of Nrf2 in the protective effects
of soluble klotho against AngII-induced oxidative stress, apoptosis
and senescence in human aortic smooth muscle cells (HASMC). We
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provide novel mechanistic evidence that soluble klotho induces the
antioxidant defence enzymes HO-1 and Prx-1, enhances Nrf2 expres-
sion and levels of reduced GSH, and attenuates AngII-mediated apop-
tosis and senescence via activation of Nrf2.
Material and methods
Culture of HASMSs
Human aortic smooth muscle cells were purchased from Lonza Group
Ltd. and cultured in DMEM (Sigma-Aldrich, UK) supplemented with
10% (v/v) foetal calf serum, 1% L-glutamine, penicillin (100 U/ml) and
streptomycin (100 lg/ml). Experiments were performed in HASMC
between passages 6 and 12. Cells were treated with either AngII
(200 nΜ) or vehicle (DMSO 0.01%, 0–72 hrs), or recombinant human
klotho (0–1 nM, 0–72 hrs) R&D systems, Abingdon, UK.
Immunoblotting
Cells were lysed with an SDS buffer (2% w/v SDS, 10% v/v glycerol,
50 mM Tris–HCl, pH 6.8) containing protease inhibitor cocktail. Total pro-
tein content was determined with the bicinchoninic acid assay (Pierce,
ThermoFisher Scientific, Northumberland, UK). Denatured samples were
separated by SDS-PAGE, transferred to a polyvinylidine difluoride (Merck
Millipore, Watford, UK) membrane and probed with the following primary
antibodies: HO-1 (BD Transduction Laboratories, Oxford, UK), Prx-1 (Gift
from Prof. Tetsuro Ishii, University of Tsukuba, Japan), Nrf2 (Santa Cruz
Biotechnology, Dallas, TX, USA) or a-tubulin (Millipore) as a reference pro-
tein. Enhanced chemiluminescence was used to visualize bands on the
membrane which were quantified by densitometric analysis.
Nrf2 knock-down
Human aortic smooth muscle cells were transfected 24 hrs after seed-
ing in 24-well plates with 40 pmol/well Nrf2-specific small interfering
RNA (siRNA) or scrambled siRNA (Santa Cruz Biotechnology) using
DharmaFECT 4 transfection reagent (GE Healthcare Life Science, Amer-
sham, UK), as previously described [18].
Measurement of intracellular-reduced GSH
A fluorometric assay was used to measure reduced GSH levels as previ-
ously described [18]. Human aortic smooth muscle cells were washed
with PBS (4°C) before lysis using 6.5% trichloroacetic acid for 10 min.
on ice. Samples were incubated with phosphate (80 mM), ethylenedi-
aminetetraacetic acid (5 mM) buffer (pH 8) containing o-phthalaldehyde
(0.1% w/v) in methanol for 25 min. Fluorescence intensity (ex: 350 nm,
em: 420 nm) was measured with a microplate reader (Chameleon V;
Hidex, Turku, Finland) and normalized to protein content using the BCA
assay.
Generation of superoxide
Superoxide generation was determined using L-012 chemiluminescence
(Wako Chemical Industries, Osaka, Japan), as previously described [18,
19]. Human aortic smooth muscle cells were treated with recombinant
human klotho (1 nM) for 24 hrs in the absence or presence of AngII
(200 nM) for the final 4-hr period and then incubated with Krebs buffer
containing L-012 (20 nM) at 37°C, in the continued presence of klotho
(1 nM) and AngII (200 nM) and in the presence or absence of superox-
ide dismutase (SOD; 100 U/ml). Luminescence was monitored over a
10-min. period at 37°C using a microplate luminometer (Chameleon V;
Hidex) and mean light units measured over 1 sec. normalized to cellular
protein content.
Assessment of apoptosis
Annexin V binding to phosphatidylserine can be used as a marker of early
apoptotic events [20]. Binding of Cy5-conjugated annexin V to HASMC
was assessed using a commercial kit (Biotium-bioscience, Fremont, CA,
USA). Cells were co-stained with Hoechst 33342 (Sigma-Aldrich) to iden-
tify nuclei and visualized using a fluorescence microscope (Nikon,
Gotenba, Japan) and images were acquired using a cooled CCD camera
(Hamamatsu Photonics, Hamamatsu, Japan). Equivalent number of cells
were captured for each field and fluorescence intensity was determined
using analysis software (Image J; NIH, Bethesda, MD, USA).
Assessment of senescence
Senescent HASMC were identified by detection of b-galactosidase (b-
gal) activity, a biomarker of cellular senescence [21], at pH 6.0 using a
senescence-associated b-gal assay kit (Cell Signalling Technology, Dan-
vers, MA, USA). Briefly, cultures were washed with PBS and fixed for
10–15 min. at room temperature. After two further washes with PBS
the cells were incubated with the b-gal staining solution (1 mg/ml 5-
bromo-4-chloro-3-indonyl-bD-galactopyranoside solution, at pH 6.0 for
12 hrs at 37°C). Cells were visualized with a microscope (TMS; Nikon)
and blue stained senescent cells identified. At least three representative
fields of view were captured for each treatment condition using a digital
camera (Canon, Tokyo, Japan).
Statistical analysis
Data denote mean  S.E.M. of measurements in at least 3–5 indepen-
dent HASMC cultures. The effects of treatment on protein expression
and GSH levels were evaluated with an unpaired Student’s t-test. Com-
parisons of two or more variables in the same experiment were con-
ducted using either a one- or two-way ANOVA with the Tukey or Sidak
multiple comparisons test respectively.
Results
Soluble klotho induces HO-1 and Prx-1
expression in a Nrf2-dependent manner and
enhances GSH levels
To assess whether klotho enhances antioxidant defences in HAMSC,
we examined the effects of recombinant human soluble klotho on the
expression of the Nrf2-regulated enzymes HO-1 and Prx-1. We
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initially demonstrated that soluble klotho enhances expression of Nrf2
in a dose-dependent manner (Fig. 1A). As shown in Figure 1B and C,
treatment of HASMC with recombinant human soluble klotho (0.5 or
1.0 nM) for 24 hrs significantly increased the expression of both HO-
1 and Prx-1. Knock-down of Nrf2 using siRNA significantly attenuated
the enhanced Nrf2, HO-1 and Prx-1 expression in response to soluble
klotho treatment (Fig. 2).
We next sought to characterize the role of klotho in regulating
levels of reduced GSH, the major intracellular thiol antioxidant [22].
HASMC were treated with soluble klotho (0.1 or 0.5 nM, 24 hrs) and
intracellular levels of GSH were measured by fluorescence. Soluble
klotho enhanced GSH levels in a dose-dependent manner (GSH nmol/
mg protein – Control: 22.7  2.0, 0.1 nM klotho: 36.7  3.5*;
0.5 nM klotho: 41.73  3.916*, *P < 0.05, n = 3).
Klotho reduces AngII-mediated superoxide
generation
To further investigate the actions of klotho in protecting against
oxidative stress in HASMC, we evaluated its effect on AngII-mediated
superoxide generation. Cells were treated with soluble klotho (1 nM)
for 24 hrs and AngII (200 nM) or vehicle were added for the last
4 hrs in the continued presence of soluble klotho. Superoxide genera-
tion was enhanced by AngII treatment (Fig. 3A), while pre-treatment
with klotho or addition of SOD (100 U/ml) during the assay signifi-
cantly attenuated the AngII-mediated superoxide generation.
Effects of soluble klotho on AngII-mediated
apoptosis
As apoptosis is a crucial event in atherosclerosis [23], we assessed
the effects of soluble klotho against AngII-mediated apoptosis in
HASMC. Cells were treated with AngII (200 nM) for 18 hrs and an
increased number of apoptotic cells was detected by annexin V fluo-
rescence (Fig. 3B). Treatment of cells with soluble klotho (1 nM,
24 hrs), prior to AngII (200 nM, 18 hrs), significantly reduced the
number of apoptotic cells. Knock-down of Nrf2 using siRNA attenu-
ated klotho-mediated protection against apoptosis, which suggests
that up-regulation of Nrf2 signalling represents an underlying mecha-
nism by which soluble klotho confers protection against Ang II-
mediated apoptosis.
Klotho reduces Ang II-mediated senescence
As AngII induces senescence of VSMC and accelerates the develop-
ment of atherosclerosis [7], we investigated whether soluble klotho
prevents AngII-mediated HASMC senescence. HASMC were treated
with AngII (200 nM, 72 hrs) to induce senescence, assessed by SA-
b-gal staining. As shown in Figure 3C, AngII increased the number of
SA-b-gal-positive senescent cells and pre-treatment with soluble
klotho (1 nM, 24 hrs) significantly decreased the number of senes-
cent cells. Knock-down of Nrf2 using siRNA abolished the protective
effects of klotho pre-treatment against AngII-induced HASMC senes-
cence.
Discussion
Activation of RAS and down-regulation of Nrf2 signalling and antioxi-
dant gene expression are associated with the development of age-
related vascular diseases [24]. In this study, we provide the first evi-
dence that the soluble form of the anti-ageing protein, klotho, acti-
vates Nrf2 in HASMC, resulting in an enhanced expression of the
antioxidant enzymes HO-1 and Prx-1 which are regulated by ARE in
their promoter regions. In addition, GSH levels were significantly
Fig. 1 Klotho induces expression of Nrf2, HO-1 and Prx-1 in HASMC. Cells were treated with human recombinant soluble klotho (0–1 nM, 24 hrs).
Representative immunoblots and densitometric analysis of Nrf2 (A), HO-1 (B) and Prx-1 (C) protein expression relative to a-tubulin. Data denote
mean  S.E.M., n = 4–5, *P < 0.05, **P < 0.01 relative to untreated cells.
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increased following klotho treatment, likely arising from the induction
of Nrf2-related genes involved in the synthesis of GSH [25]. Our find-
ings also demonstrate that klotho attenuates AngII-induced apoptosis
and senescence via activation of the Nrf2 signalling pathway.
AngII is known to be an inducer of ROS production in VSMC
which contributes to age-related vascular inflammation and atheroge-
nesis [26]. NADPH oxidases (Nox) and the mitochondrial respiratory
chain represent the major molecular sources of ROS generation in
response to AngII in VSMC [27, 28], which can express multiple Nox
isoforms, including Nox1, Nox2, Nox4 and Nox5 [29]. Although Nox2
is found in all vascular cells, it is expressed to a lesser extent in arte-
rial VSMC, whereas Nox4 is likely to be the main isoform expressed
in human aortic VSMC [30].
Enhanced expression of HO-1 and Prx-1 has been shown to pro-
tect against atherosclerosis in murine models [9, 31, 32]. We have
previously reported that Nrf2 mediates an important protective
response to oxidative stress through the expression of HO-1 and
Prx-1 in human and murine VSMC [33–35]. In animal models of
vascular disease, activators of Nrf2 signalling can restore cellular
redox homoeostasis by increasing the expression of antioxidant
enzymes [9].
A reciprocal regulation between klotho and Nrf2 signalling has
been shown in studies using klotho mutant mice [36, 37]. Klotho defi-
ciency in vivo has been reported to be associated with decreased hep-
atic cytoplasmic and nuclear levels of Nrf2, conversely klotho
overexpression results in an increase in nuclear Nrf2 and activation of
the ARE in the promoter of antioxidant genes [36]. Furthermore,
down-regulation of klotho in airway epithelial cells has been shown to
contribute to the activation of oxidative and inflammatory pathways
and is associated with diminished Nrf2 signalling [38]. We demon-
strate that soluble klotho is an inducer of Nrf2 in HASMC in a dose-
dependent manner. Treatment of HASMC with soluble klotho prior to
AngII exposure significantly attenuated ROS generation, which is con-
sistent with the existing literature on the protective effects of klotho in
the vasculature. Although Six et al. reported an acute increase in ROS
generation by soluble klotho in HASMC [39], klotho gene delivery in
rat aortic VSMC results in protection against AngII-induced superox-
ide production via down-regulation of Nox2 protein expression medi-
ated by the cAMP-PKA pathway [40]. In cardiomyocytes from rodents
with chronic kidney disease, soluble klotho has been reported to inhi-
bit ROS generation through the attenuation of Nox2 and Nox4 expres-
sion [41]. A reduction in renal mitochondrial oxidative stress and
DNA damage has been shown in klotho transgenic mice [42]. Taken
together, the reduction in ROS generation observed in our study fol-
lowing klotho pre-treatment is likely to have arisen from diminished
AngII-induced Nox and mitochondrial ROS generation as well as
increased scavenging of ROS mediated by the enhanced expression
of Nrf2-regulated antioxidant enzymes.
We have provided the first demonstration that Nrf2-mediates the
increase in expression of HO-1 and Prx-1 in VSMC following treat-
ment with soluble klotho. This is likely to have occurred through
nuclear localization of Nrf2 and binding to the ARE in the promoter
regions of Nrf2-responsive genes [9]. Although the effect of AngII on
Nrf2 signalling was not investigated in this study, AngII has been
shown to elicit nuclear accumulation of Nrf2 in aortic VSMC from nor-
motensive but not spontaneously hypertensive rats, as an antioxidant
defence response to enhanced ROS generation and oxidative stress
[6].
In addition to oxidative stress, VSMC apoptosis contributes to
atherogenesis [43]. The present study demonstrates that soluble
klotho protects HASMC from AngII-induced apoptosis. The anti-apop-
totic and antioxidant effects of klotho have been previously shown in
cultured endothelial cells and reported to be linked with the p53/p21
and mitogen-activated protein kinase pathways [44]. Renin angioten-
sin system activation is a characteristic event in the progression of
cardiovascular disease and is associated with klotho deficiency [45].
Conversely, administration of exogenous soluble klotho may offer
cardiovascular-renal protection in chronic kidney disease by blunting
the activation of RAS [45]. A bidirectional link between klotho and
RAS has been described and confirmed by previous work from our
group [46, 47].
Smooth muscle cell senescence is associated with the develop-
ment of vascular disease [48]. We are the first to show that soluble
Fig. 2 Nrf2-mediated induction of HO-1 and Prx-1 in HASMC. Cells were
transfected with scrambled or Nrf2 siRNA prior to treatment with sol-
uble klotho (1 nM, 24 hrs) and Nrf2 (A) and HO-1 (B) expression deter-
mined ay immunoblot analyses. (C) Densitometric analysis of Nrf2, HO-
1 and Prx-1 protein expression relative to a-tubulin following klotho
treatment (1 nM, 24 hrs) in control (open bars) or Nrf2-deficient cells
after siRNA knock-down (solid bars). Data denote mean  S.E.M.,
n = 3, ***P < 0.001.
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klotho attenuates AngII-induced senescence in HASMC mediated by
Nrf2 as knock-down of Nrf2 attenuated the protective effect of klotho.
Protection against hydrogen peroxide-mediated senescence by klotho
has been previously reported in human fibroblasts and umbilical vein
endothelial cells but the role of Nrf2 was not assessed [49–51].
This study represents a novel report on the antioxidant, anti-apop-
totic and anti-senescence effects of soluble klotho in HASMC medi-
ated by an up-regulation of Nrf2 signalling and induction of
antioxidant enzymes. Nrf2 has a role in vasoprotection and it is known
to be regulated by intracellular redox status [52]. It is likely that
Fig. 3 Soluble klotho attenuates AngII-mediated superoxide generation, apoptosis and senescence in HASMC. Superoxide generation (A) was mea-
sured by L-012 chemiluminescence and mean light units (MLU) measured in live cells after incubation with soluble klotho (1 nM, 24 hrs) in the
absence or presence of angiotensin II (AngII, 200 nM) for the final 4 hrs. Some cells were treated with superoxide dismutase (SOD, 200 U/ml) dur-
ing the measurement period. Data denote mean  S.E.M., n = 4, ***P < 0.001 relative to control cells, ####P < 0.0001 relative to cells treated
with AngII. Apoptosis (B) was assessed by annexin V binding in cells treated with AngII (200 nM, 18 hrs) in the presence or absence of soluble
klotho pre-treatment (1 nM, 24 hrs). Graph shows quantification of annexin V fluorescence following Nrf2 siRNA knock-down (solid bars) or trans-
fection with scrambled siRNA (open bars) prior to treatments with soluble klotho. Data denote mean  S.E.M., n = 3, **P < 0.01, ***P < 0.001
relative to untreated cells, ##P < 0.01 relative to cells transfected with scrambled siRNA prior to AngII treatment, $$$P < 0.001 relative to respec-
tive cells transfected with scrambled siRNA. Senescence (C) was assessed using the senescence-associated b-galactosidase (SA-b-gal) activity
assay. Following transfection with scrambled or Nrf2 siRNA, cells were pre-incubated with soluble klotho (1 nM, 24 hrs) prior to treatment with
AngII (200 nM, 72 hrs) in the continued presence of soluble klotho. Cells were stained for SA-b-gal activity and the number of senescent cells
quantified by image analyses as a percentage of total cell number in at least 3 fields of view. Data denote mean  S.E.M., n = 3, *P < 0.05,
**P < 0.01 relative to respective untreated cells, ##P < 0.01 relative to scrambled siRNA transfected cells treated with AngII alone, $$P < 0.01 rela-
tive to control cells transfected with scrambled siRNA, †P < 0.05 relative to scrambled siRNA-transfected control cells.
ª 2016 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
5
J. Cell. Mol. Med. Vol XX, No X, 2016
protein kinases may regulate the activation of Nrf2 following treat-
ment with soluble klotho [37]. The activation of GSK3-b diminishes
antioxidant gene expression by enhancing nuclear exclusion and inac-
tivation of Nrf2 [53]. Klotho has been identified as inhibitor of GSK3-b
in renal epithelial cells [54], thus suppression of GSK3-b signalling by
klotho represents a possible mechanism by which it enhances Nrf2-
mediated antioxidant enzyme expression and confers protection
against AngII in HASMC. Additional studies are necessary to further
elucidate the cellular signalling pathways that link soluble klotho with
Nrf2 signalling.
In conclusion, our findings provide novel mechanistic insights
into the vasculoprotective effects of soluble klotho mediated by the
Nrf2 antioxidant signalling pathway, and emphasize the therapeutic
potential of targeting klotho to activate Nrf2 in cardiovascular and
other ageing-related diseases.
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